Needham cuts Merit Medical stock price target to $90 on valuation

Needham cut Merit Medical Systems’ price target to $90 from $101 while keeping a Buy rating, citing peer multiple contraction; BofA also lowered its target to $80 from $100 with a Neutral rating. The company’s Q1 2026 results beat estimates, with revenue of about $382 million and EPS of $0.94, while management slightly raised revenue guidance and maintained EPS guidance. Growth slowed to 3.7% year over year, and gross margin was pressured by a 120 bps tariff impact, partly offset by a 50 bps rise in operating margin.

Analysis

The market is treating MMSI like a de-risked cash compounder, but the real signal is that operating leverage is still intact even as top-line momentum decelerates. That combination usually supports downside compression on earnings revisions, not a collapse in intrinsic value, especially when free cash flow is improving and the balance sheet can absorb tariff noise. The multiple cut from peers is more about sector de-rating than company-specific deterioration, which means the stock can re-rate upward quickly if medical-device multiples stabilize.

The key second-order issue is margin durability: tariff-driven gross margin pressure is small today, but if sourcing costs continue to rise, it will start to offset the operating discipline that’s currently masking slower organic growth. That creates a bifurcation versus device peers with higher exposure to consumables or outsourced manufacturing; MMSI may hold up better than the market expects if it can pass through pricing or mix-shift toward higher-margin products. Conversely, any disappointment in WRAPSODY uptake will be punished more than the headline guidance implies because the market is already anchoring on a modest 2026 contribution.

Consensus seems to be missing that this is less a growth story than a valuation-and-quality setup. When a name is near a 52-week low, has a solid current ratio, and is still beating estimates, the right question is not whether growth is slowing, but whether estimate revisions have gotten low enough to absorb continued mid-single-digit expansion. If peer multiples stop contracting, the stock can rerate 15-20% without any fundamental surprise; if they keep compressing, downside is likely capped unless margins roll over materially.

Key Decisions for Investors

• Go long MMSI on weakness in the $64-$68 range with a 3-6 month horizon; target a 15-20% re-rating if sector multiples stabilize, with stop-loss on sustained breaks below the 52-week low.
• Use a call spread in MMSI (6-9 months) rather than outright stock if you want upside to multiple re-rating while limiting exposure to tariff-driven margin pressure; best risk/reward if implied volatility stays subdued.
• Pair trade: long MMSI / short a more valuation-sensitive medtech peer with lower FCF conversion and higher tariff exposure over the next 1-2 quarters; the trade benefits if the market rewards balance-sheet strength and estimate beats over beta.
• Reduce exposure or hedge if organic growth prints stay below ~4% for two consecutive quarters; that would likely trigger another round of estimate cuts and overwhelm any support from operating margin.
• Watch WRAPSODY commercialization closely over the next 6-12 months; if sales accelerate above the current run-rate, the stock should outperform on a faster-than-expected mix shift, but if adoption stalls, trim longs aggressively.